Vinflunine.
Pierre Fabre SA, in collaboration with Bristol-Myers Squibb Co, is developing vinflunine, a fluorinated vinca alkaloid, as a potential anticancer agent.
Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford, BD7 1DP, UK. S.D.Shnyder@Bradford.ac.uk
Steven D
SD
Shnyder
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D042783:Endothelial Cells / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D009369:Neoplasms / Q000188:drug therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; C111217:vinflunine; D014747:Vinblastine